A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

NCT05780034 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Accutar Biotechnology Inc